Document 0551
 DOCN  M9460551
 TI    The new frontier: gene and oligonucleotide therapy.
 DT    9404
 AU    Schreier H; Center for Lung Research, Vanderbilt University School of;
       Medicine, Nashville, TN 37232-2650.
 SO    Pharm Acta Helv. 1994 Jan;68(3):145-59. Unique Identifier : AIDSLINE
       MED/94167392
 AB    Gene and oligonucleotide therapy are emerging as clinically viable
       therapeutic regimens for genetic, neoplastic, and infectious diseases.
       Approaches include insertion of human genes in viral vectors including
       recombinant retrovirus, adenovirus, adeno-associated virus, and herpes
       simplex virus-1, or recombinant bacterial plasmids. Viral vectors
       transfect cells directly; plasmid DNA is delivered with the help of
       cationic liposomes (lipofection), polylysine conjugates, gramicidin S,
       artificial viral envelopes or other such intracellular carriers. Major
       areas of interest include replacement of the cystic fibrosis
       transmembrane regulator gene and the alpha 1-antitrypsin gene; arrest of
       human immunodeficiency virus infection; and reversal of tumorigenicity
       and cancer immunization, among others. Oligonucleotide therapy is
       principally focusing on the same areas, although the approach is to halt
       DNA transcription or messenger RNA translation with code-blocking
       triple-helix-forming or antisense oligomers. Contributions from the
       pharmaceutical sciences are expected in pharmaceutical chemistry, drug
       delivery systems design, analytical chemistry, and biopharmaceutics.
 DE    Animal  *Gene Therapy  Human  *Oligonucleotides  Support, Non-U.S. Gov't
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).